Hoth Therapeutics IncHOTH announced Phase 1b trial data for BioLexa in adult patients with mild-to-moderate atopic dermatitis.
Using the SCORAD as a clinical tool for assessing the severity of atopic dermatitis (scale) and EASI score, a tool used to measure the extent (area) and severity of atopic eczema, all patients showed improvement during the study compared to the day one score.
Using the EASI scale, 100% of patients showed clinically-relevant improvement >50% compared to Day 1 during the entire 28-day study treatment period.
Using SCORAD, 60% of patients showed overall clinically relevant improvement (>35% improvement) during the study compared to the Day 1 score.
42% of patients maintained improvement from day 14 to day 28, supporting the long-term effect of BioLexa.
A clinically relevant reduction in the total body surface area affected by atopic dermatitis was observed in 71% of patients treated with BioLexa. The total reduction of these patients ranged from 37.5% to 71.4%.
BioLexa was well tolerated, with no serious adverse events and no drug-related treatment-emergent adverse events observed.
Price Action: HOTH shares are up 25.2% at $7.13 on the last check Monday.
